Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1056721

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with pharmaceutical companies on access to medication for bleeding disorders in the event of the UK leaving the EU without a withdrawal agreement.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	218233
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Secretary of State for Health and Social Care discusses a wide range of issues with a number of stakeholders and other Government Departments.</p><p> </p><p>Medicines to treat bleeding disorders are in scope of our medicines contingency plans because these are licensed medicines. Contingency work for blood and blood components is being led by NHS Blood and Transplant.</p><p> </p><p>We understand that these medicines are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medications for bleeding disorders and other essential medicines for patients is not disrupted. In developing our plans, we have received very good engagement from industry who share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to continue unimpeded after the UK leaves the EU on 29 March 2019.</p><p> </p><p>We have asked companies to ensure a minimum of six weeks additional supply over and above existing business as usual stocks by 29 March 2019, or to make provision for airfreight of medicines that cannot be stockpiled.</p><p> </p><p>That is why we are working to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely in to the UK. Medicines and other medical products will be prioritised on these routes to ensure that the flow of all these products will continue unimpeded after 29 March 2019.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 12/02/2019 17:42:06 answering member 1585 label Biography information for Stephen Hammond
tabling member	1533 label Biography information for Dame Diana Johnson

1056004

registered interest
date	06/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of medications for bleeding disorders in the event that the UK leaves the EU without a deal.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	217506
answer	answer is ministerial correction date of answer 11/02/2019 answer text <p>Treatments for bleeding disorders include pharmaceutical medicines as well as products derived from donated blood, such as clotting factors. As these are licensed medicines, they will be in scope of our medicine supply contingency plans. Contingency work for blood and blood components is being led by NHS Blood and Transplant.</p><p> </p><p>We understand that these medicines are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medications for bleeding disorders and other essential medicines for patients is not disrupted.</p><p> </p><p>In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from, or via, the EU/European Economic Area (EEA) asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.</p><p> </p><p>We recognise, however, that certain medicines cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a ‘no deal’ exit.</p><p> </p><p>Whilst the stockpiling medicines and alternative air freight remains a critical part of our ‘no deal’ medicine supply contingency plans, we are also supplementing these with additional actions.</p><p> </p><p>We have further secured sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely in to the UK. Medicines and other medical products will be prioritised on these routes to ensure that the flow of all these products will continue unimpeded after 29 March 2019.</p><p> </p><p>Throughout enacting our plans, we have received very good engagement from industry who share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a ‘no deal’ EU exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 11/02/2019 11:34:59 answering member 1585 label Biography information for Stephen Hammond
tabling member	1533 label Biography information for Dame Diana Johnson

456377

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether appropriate treatment for patients with plasma disorders such as haemophilia and primary immunodeficiency, as provided for under the statutory scheme for branded medicines, will continue to be provided following the review of that scheme by the Department of Health.
tabling member printed	Lord Walton of Detchant
uin	HL6608
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>We are continuing to consider carefully all the consultation responses. It is important we get these changes right for patients, the National Health Service and industry. We want to look in particular at the impact on small and medium sized businesses, while securing the medicines patients need at a cost which the NHS can afford.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:17:07 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1716 label Biography information for Lord Walton of Detchant

422640

registered interest
date	20/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, what assessment his Department has made of the date on which he will issue a tender for extended half-life products.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	12557
answer	answer is ministerial correction date of answer 30/10/2015 answer text <p>The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.</p><br /><p>NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.</p><br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 12558 question first answered 30/10/2015 12:05:33 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

422641

registered interest
date	20/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	12558
answer	answer is ministerial correction date of answer 30/10/2015 answer text <p>The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.</p><br /><p>NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.</p><br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 12557 question first answered 30/10/2015 12:05:33 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen